Announcements Trials
Browse Landscape

Phase

Phase 2/3 1Phase 1/2 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Glioblastoma 2Recurrence 1Meningeal Carcinomatosis 1Diffuse Intrinsic Pontine Glioma 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Temozolomide 100Radiotherapy 49Magnetic Resonance Spectroscopy 38Radiation 28Specimen Handling 25pembrolizumab 22Bevacizumab 22Lomustine 16Nivolumab 14Surgical Procedures, Operative 10atezolizumab 8Cyclophosphamide 8Biopsy 8abemaciclib 7Ipilimumab 7fludarabine 6Radiotherapy, Intensity-Modulated 6Carboplatin 6Aminolevulinic Acid 6olaparib 5Metformin 5Drug Therapy 5Diet, Ketogenic 5Dianhydrogalactitol 5poly ICLC 4cemiplimab 4Radiosurgery 4Photons 4Leukapheresis 4Immunoglobulin G 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Glioblastoma × GDC-0084 × 1 year × Clear all
NCT03970447 2026-06-03

GBM AGILE

Global Coalition for Adaptive Research

Phase 2/3 Recruiting
2,250 enrolled
CNS

Glioblastoma, Recurrence

NCT07391215 2026-02-05

5G-PEARL

Institute of Cancer Research, United Kingdom

Phase 1/2 Recruiting
64 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡